Drug Trial Radar · NCT00597584
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
Last checked: Nov 19, 2026Latest source record: Mar 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
823
Actual
Start
Oct 2007
Primary completion
Jul 2009
Study completion Jan 2010
Sponsor
- Lead sponsor
- AffymaxIndustry
- Sponsor type
- Industry
- Collaborators
- Takeda
- First posted
- Jan 18, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.
Conditions
- Chronic Renal Failure
- Chronic Kidney Disease
- Anemia
Interventions
peginesatideDrug
Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
Epoetin alfa or Epoetin betaDrug
Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Hemoglobin Between Baseline and the Evaluation PeriodTime frame: Baseline to Weeks 29-36
Locations
84 sites in 9 countries. Site status is shown where the registry gives one.
Research Facility
Phoenix, Arizona
Research Facility
Hot Springs, Arkansas
Research Facility
McGehee, Arkansas
Research Facility
Pine Bluff, Arkansas
Research Facility
Bakersfield, California
Research Facility
Glendale, California
Research Facility
Los Angeles, California
Research Facility
Los Angeles, California
Research Facility
Los Angeles, California
Research Facility
Riverside, California
Research Facility
Simi Valley, California
Research Facility
Whittier, California
Research Facility
Yuba City, California
Research Facility
Westminster, Colorado
Research Facility
Lauderdale Lakes, Florida
Research Facility
Miami, Florida
Research Facility
Pinecrest, Florida
Research Facility
Flossmoor, Illinois
Research Facility
Hines, Illinois
Research Facility
Louisville, Kentucky
Research Facility
Rockville, Maryland
Research Facility
Springfield, Massachusetts
Research Facility
Detroit, Michigan
Research Facility
Detroit, Michigan
Research Facility
Brookhaven, Mississippi
Research Facility
Brooklyn, New York
Research Facility
Flushing, New York
Research Facility
The Bronx, New York
Research Facility
Asheville, North Carolina
Research Facility
Toledo, Ohio
Research Facility
Oklahoma City, Oklahoma
Research Facility
Erie, Pennsylvania
Research Facility
Philadelphia, Pennsylvania
Research Facility
Providence, Rhode Island
Research Facility
Orangeburg, South Carolina
Research Facility
Arlington, Texas
Research Facility
Houston, Texas
Research Facility
San Antonio, Texas
Research Facility
Fairfax, Virginia
Research Facility
Burgas, Bulgaria
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.